Clinical trials: Drug/Agent Toxicity by Tissue/Organ
Anemia, Breast Cancer
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with cancer who are receiving chemotherapy.
- Conditions
- Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
- Trial name
- NCT00003600
- Testing
- epoetin alfa
- Where
- 21 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox.
- Trial name
- NCT00006345
- Testing
- denileukin diftitox, dexamethasone
- Where
- 11 sites in United States
- Sponsor
- Ligand Pharmaceuticals
Respiratory Insufficiency, Overdose of Opiate
ARM-ED: Advanced Respiratory Monitoring Events in Drug Toxicity
There is a drug-related death crisis in Scotland. The majority of these deaths have involved the misuse of opiates (e.g. heroin) and benzodiazepines (e.g. valium) which cause an individual to stop breathing.
- Conditions
- Respiratory Insufficiency, Overdose of Opiate, Sedative Overdose, Sedative Toxicity
- Trial name
- ARM-ED (NCT05358132)
- Testing
- Pneumowave Device placement and data capture
- Where
- United Kingdom
- Volunteers
- 78 people
- Sponsor
- NHS Greater Glasgow and Clyde
Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.
- Trial name
- NCT00024427
- Testing
- fluorouracil, gemcitabine hydrochloride, triacetyluridine
- Where
- 29 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Wellstat Therapeutics
Drug Toxicity
Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects
To Evaluate the safety and tolerability after KD101 single oral dosing in healthy male subjects To Evaluate the pharmacokinetic property after KD101 single oral dosing in healthy male subjects To Evaluate the effect of food on…
- Trial name
- NCT01979380
- Testing
- KD101
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation…
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Trial name
- NCT00003583
- Testing
- amifostine trihydrate, cisplatin, etoposide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Mental Disorders, Metabolism Medication Toxicity
Pharmacogenomic Profiling of Pediatric Patients
The purpose of this study is to determine the proportion of children presenting to a pediatric emergency department with an acute mental health/behavioral crisis or clinical drug toxicity who have a "match" or "mismatch" between…
- Conditions
- Mental Disorders, Metabolism Medication Toxicity, Pediatric Disorder
- Trial name
- NCT02770339
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham
Maximum Tolerated Dose, GIST
Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)
This is a single-arm, two cohort, open label phase I/II clinical trial studying the combination of oral imatinib 400 mg, once daily, and oral selinexor given once weekly (Cohort A); and single-agent oral selinexor 60 mg BIW…
- Conditions
- Maximum Tolerated Dose, GIST, Metastatic Adult Soft Tissue Sarcoma, Drug Toxicity
- Trial name
- SeliGIST (NCT04138381)
- Testing
- Selinexor, Imatinib
- Where
- 6 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Gestational Trophoblastic Tumor, Effects of Chemotherapy
Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma （GTN） Patients With Score of 5-6
In this study, a prospective, multicenter randomized controlled study was conducted to compare the clinical efficacy and toxicity response of combination MTX+ACTD multi-course regimen in low-risk GTN patients with score 5-6 with…
- Conditions
- Gestational Trophoblastic Tumor, Effects of Chemotherapy, Drug Toxicity
- Trial name
- NCT03885388
- Testing
- MTX, MTX+ACTD
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Diarrhea, Drug/Agent Toxicity by Tissue/Organ
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
- Trial name
- NCT00093353
- Testing
- cefixime, irinotecan hydrochloride, temozolomide
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Long QT Syndrome, Drug Toxicity
Genetics of QT Prolongation With Antiarrhythmics
To assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in patients being loaded with dofetilide or sotalol.
- Trial name
- DOFEGEN (NCT02439658)
- Testing
- Dofetilide and/or sotalol
- Where
- 5 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Massachusetts General Hospital
Melanoma Stage III, Melanoma Stage IV
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV
- Trial name
- NCT04305145
- Testing
- Infliximab, Methylprednisolone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
ALL, Childhood, Pediatric Cancer
Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia
A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL).
- Conditions
- ALL, Childhood, Pediatric Cancer, Toxicity, Drug, Adverse Drug Event
- Trial name
- MPGx-INDALL (NCT05512169)
- Where
- 2 sites in India
- Volunteers
- 556 people
- Sponsor
- University of Geneva, Switzerland
Volunteers Repeated Drug Poisoning, Alcoholic
Repeated Voluntary Drug Intoxication (IMVr): Characterization of a New Addictive Behavior by Clinical Phenotyping and Functional Imaging
France is one of the European countries with the highest rate of death by suicide, more than 10 400 deaths each year, about 16 people out of 100 000.
- Conditions
- Volunteers Repeated Drug Poisoning, Alcoholic, Volunteers
- Trial name
- Phenot IMVr (NCT02889042)
- Testing
- MRI and biological assessment
- Where
- France
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Overdose, Drug, Drug Use
ASSIST: A Surveillance Study of Illicit Substance Toxicity
There is a drug-related death crisis in Scotland. This study aims to collaborate with Public Health Scotland in order to assess the feasibility of introducing a surveillance system to the Emergency Department to highlight illicit…
- Conditions
- Overdose, Drug, Drug Use, Drug Abuse, Drug Toxicity
- Trial name
- ASSIST (NCT05329142)
- Testing
- Surplus sample toxicology analysis
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- NHS Greater Glasgow and Clyde
Ankylosing Spondylitis, Therapeutic Agent Toxicity
A Randomized Open-labeled Study for Comparing Methods of Using Imrecoxib to Treat AS
The selective cox-2 inhibitor has been widely used in the treatment of Ankylosing spondylitis (AS). The Imrecoxib is a new cox-2 inhibitor. But the treatment strategy has not been decided yet.
- Trial name
- NCT04400786
- Testing
- intermittent treatment, continuous treatment
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Shanghai Zhongshan Hospital
Omeprazole
Evaluation of the Prophylactic Use of Omeprazole in Patients Admitted to the State Hospital of Américo Brasiliense
Introduction. The prevalence of the use of drugs that act on the gastric system has increased in the population. Omeprazole is an inhibitor of the protons pump and has a widespread use, mainly as a prophylactic to prevent reflux…
- Trial name
- NCT02278432
- Volunteers
- 427 people
- Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
Cancer, Drug Toxicity
Atrial Fibrillation in Active Cancer Patients
Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines.
- Conditions
- Cancer, Drug Toxicity, Atrial Fibrillation, Cardiovascular Complication
- Trial name
- AFIB-CANCER (NCT04696081)
- Testing
- occurence of atrial fibrillation
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Caen
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
- Trial name
- NCT00074165
- Testing
- Rituxan, Cyclophosphamide, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- OHSU Knight Cancer Institute
Poison Drug, Poison;Medicinal;Wrong Drug
Trends of Acute Intoxication in Poison Control Centre
the study aim to investigate the trend of poisoning and its causative agents among different egyption people ages between 2015 and 2019
- Conditions
- Poison Drug, Poison;Medicinal;Wrong Drug, Poisoning
- Trial name
- NCT05098418
- Testing
- Poison
- Where
- Egypt
- Volunteers
- 10,000 people
- Sponsor
- MTI University